Asset Details
Do you wish to reserve the book?
Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology
Do you wish to request the book?
Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology
2024
Overview
Chronic histiocytic intervillositis of unknown origin (CHI) is a rare placental disorder associated with adverse pregnancy outcomes, frequent recurrence, and a lack of effective preventive strategies. Recent insights indicate a potential link between CHI-associated inflammatory lesions and the inflammasome pathway, suggesting innovative therapeutic avenues. Here we show a potential role of the inflammasome pathway in CHI through comprehensive transcriptomic analysis of grade 2 or 3 histopathologic CHI samples, paired with placental controls. Additionally, we present case studies of three individuals with recurrent CHI, who have undergone treatment with anakinra and colchicine throughout pregnancy, resulting in improved perinatal outcomes. Notably, all cases are characterized by the birth of healthy, full-term infants, with reduced or absent intervillositis recurrence. Placental assessment unveils heightened activation of the NLRP3-PYCARD inflammasome pathway and IL-1β processing in CHI samples, with downregulation observed in treated pregnancy samples, devoid of intervillositis. Collectively, these findings suggest a potential therapeutic role for targeting the inflammasome pathway in preventing recurrent CHI in pregnant individuals.
Chronic histiocytic intervillositis of unknown origin is a rare but serious and hard-to-prevent condition, leading to repeated pregnancy losses. Here authors show that high-grade cases are associated with inflammasome activation in placental samples, and they report the birth of healthy full-term infants following sustained inflammasome inhibition in three high-risk pregnancies.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/51
/ 38
/ 38/39
/ Adult
/ CARD Signaling Adaptor Proteins - genetics
/ CARD Signaling Adaptor Proteins - metabolism
/ Chorionic Villi - metabolism
/ Female
/ Humanities and Social Sciences
/ Humans
/ Infants
/ Interleukin 1 receptor antagonist
/ Interleukin 1 Receptor Antagonist Protein - therapeutic use
/ Interleukin-1beta - genetics
/ Interleukin-1beta - metabolism
/ NLR Family, Pyrin Domain-Containing 3 Protein - genetics
/ NLR Family, Pyrin Domain-Containing 3 Protein - metabolism
/ Placenta
/ Placenta Diseases - drug therapy
/ Placenta Diseases - pathology
/ Science
